Natriumhydrogencarbonat Deltamedica (Sodium Hydrogen Carbonate)

Sodium hydrogen carbonate, the active ingredient in Natriumhydrogencarbonat Deltamedica, is a buffering agent presented as an injectable solution for intravenous use. It is employed to correct metabolic acidosis, support cardiac resuscitation, and manage hyperkalemia and certain drug intoxications in acute care settings.

GNH USA supplies Natriumhydrogencarbonat Deltamedica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, ensuring quality, regulatory compliance, and reliable cold‑chain logistics across all markets.

Natriumhydrogencarbonat Deltamedica is used to address acid‑base disturbances and electrolyte imbalances in critical care. - Metabolic acidosis: restores normal pH by providing bicarbonate ions, reducing acidity. - Cardiac arrest (resuscitation): improves myocardial contractility and counteracts acidemia during emergency CPR. - Hyperkalemia: shifts potassium intracellularly by correcting acidosis, aiding rapid potassium reduction. - Certain drug intoxications: neutralizes acidic toxins and supports renal elimination in overdose situations.

Administration of sodium hydrogen carbonate may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Hypernatremia: elevated serum sodium levels that may cause thirst, hypertension, or neurological symptoms. - Metabolic alkalosis: excessive increase in blood pH leading to dizziness, nausea, or muscle twitching. - Hypokalemia: reduced potassium concentration that can result in muscle weakness or cardiac effects. - Fluid overload: increased intravascular volume that may produce peripheral edema or shortness of breath.

Serious or Rare Side Effects: - Pulmonary edema: accumulation of fluid in the lungs, potentially causing respiratory distress. - Severe cardiac arrhythmias: dangerous rhythm disturbances such as ventricular tachycardia linked to electrolyte imbalance. - Seizures: neurologic events triggered by extreme alkalosis or electrolyte shifts.

Prior to using Natriumhydrogencarbonat Deltamedica, clinicians should observe several safety considerations. - Monitor electrolytes: regularly check serum sodium, potassium, and bicarbonate levels during therapy. - Adjust infusion rate: avoid rapid administration to reduce risk of volume overload and sudden pH changes. - Assess cardiac function: use caution in patients with heart failure or ischemic heart disease. - Evaluate renal function: impaired kidneys may limit bicarbonate excretion and increase toxicity risk. - Contraindications: avoid in patients with severe metabolic alkalosis or known hypersensitivity to sodium bicarbonate. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium hydrogen carbonate can interact with other medications, affecting their efficacy or safety.

Major Interactions (Avoid): - Calcium-containing solutions: precipitation may occur, compromising IV line patency. - Other alkalinizing agents: combined use can cause severe metabolic alkalosis. - Certain antibiotics (e.g., aminoglycosides): altered renal clearance may increase toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: enhanced potassium loss may exacerbate hypokalemia. - ACE inhibitors or ARBs: additive effects on potassium balance require monitoring. - Digitalis glycosides: electrolyte shifts can increase risk of arrhythmias. - Anticoagulants: changes in plasma pH may affect drug binding and activity.